Impax To Acquire Tower Holdings, Inc. And Lineage Therapeutics Inc.

-- Acquisitions includes operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC -- Provides Portfolio of Growing, High-Margin, Complex Generic and Branded Products -- Enhances Generic Pipeline with Near-Term Opportunities -- Adds a Leading Franchise in a New Specialty Brand Therapeutic Area -- Diversifies and Expands Manufacturing and Supply Chain Capabilities --- Immediately Accretive with Opportunities for Operational Synergies --

HAYWARD, Calif., Oct. 9, 2014 -- Impax Laboratories, Inc. (IPXL) today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.

Actavis to Acquire Durata Therapeutics, Inc.

- Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings -
- Enhances Actavis' Long-term Growth Profile 2015+ -
- Experienced Development and Commercial Team Bolsters Actavis' Infectious Disease Expertise
- Leverages Actavis' Hospital Sales and Marketing Capabilities

DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 -- Actavis plc (ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. (DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, today announced that they have entered into a definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675 million in the aggregate, and contingent value rights (CVRs) entitling the holder to receive additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE^TM are achieved.  Actavis expects the acquisition to be accretive by the end of the first year.

Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology

TORONTO, Aug. 28, 2014  -- Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an enhancement of its Rexista(TM) abuse-deterrence technologies with a significant improvement designed to prevent overdose when more pills than prescribed are swallowed intact. Intellipharmaceutics' new platform technology is branded PODRAS(TM) (Paradoxical OverDose Resistance Activating System).

Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.

Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (GSK) to acquire the U.S rights to Treximet® on May 14. Pernix’s expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet^®. The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.